반응식
[CH2:1]([O:3][C:4](=[O:29])[CH2:5][CH2:6][NH:7][C:8]([NH:10][C:11]1[S:12][C:13]([C:17]2[CH:22]=[CH:21][N:20]=[C:19](N3CCOCC3)[CH:18]=2)=[C:14]([CH3:16])[N:15]=1)=[O:9])[CH3:2].C(OC(=O)CNC(NC1SC(C2C=CN=CC=2)=C(C)N=1)=O)C>>[CH2:1]([O:3][C:4](=[O:29])[CH2:5][CH2:6][NH:7][C:8]([NH:10][C:11]1[S:12][C:13]([C:17]2[CH:18]=[CH:19][N:20]=[CH:21][CH:22]=2)=[C:14]([CH3:16])[N:15]=1)=[O:9])[CH3:2]참가 물질
3
실험 절차
This compound is prepared by an analogous procedure to 3-{3-[4-Methyl-5-(2-morpholin-4-yl-pyridin-4-yl)-thiazol-2-yl]-ureido}-propionic acid ethyl ester (Example 14) by replacing 4-Methyl-5-(2-morpholin-4-yl-pyridin-4-yl)-thiazol-2-ylamine hydrobromide (13b) with 4-methyl-5-pyridin-4-yl-thiazol-2-ylamine (see Example 16 for reference).
출처 및 근거
- ORD 기록
- ord-db1c140c7b3346bd82afd42fa84d251a
- 출처 데이터셋
- uspto-grants-2013_03
- 특허 번호
- US08404684B2
연결된 노트
불러오는 중…